| __timestamp | Amicus Therapeutics, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 461543000 |
| Thursday, January 1, 2015 | 76943000 | 634806000 |
| Friday, January 1, 2016 | 104793000 | 661905000 |
| Sunday, January 1, 2017 | 149310000 | 610753000 |
| Monday, January 1, 2018 | 270902000 | 696328000 |
| Tuesday, January 1, 2019 | 286378000 | 715007000 |
| Wednesday, January 1, 2020 | 308443000 | 628116000 |
| Friday, January 1, 2021 | 272049000 | 628793000 |
| Saturday, January 1, 2022 | 276677000 | 649606000 |
| Sunday, January 1, 2023 | 152381000 | 746773000 |
| Monday, January 1, 2024 | 747184000 |
Unlocking the unknown
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.
BioMarin has consistently invested in R&D, with expenses peaking in 2023 at approximately $747 million, marking a 62% increase from 2014. This steady growth underscores BioMarin's dedication to advancing its pipeline of therapies.
Conversely, Amicus Therapeutics has shown more variability in its R&D spending. After a significant rise to $308 million in 2020, expenses dropped by 50% in 2023. This fluctuation may reflect strategic shifts or financial constraints.
These trends highlight the dynamic nature of R&D investment in the biotech sector, where strategic decisions can significantly impact a company's innovation trajectory.
Research and Development Expenses Breakdown: Novartis AG vs BioMarin Pharmaceutical Inc.
R&D Insights: How Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc. Allocate Funds
Vertex Pharmaceuticals Incorporated vs Amicus Therapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Zoetis Inc. and BioMarin Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
BioMarin Pharmaceutical Inc. or Pharming Group N.V.: Who Invests More in Innovation?
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs Viridian Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Blueprint Medicines Corporation and Amicus Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. or Amicus Therapeutics, Inc.: Who Invests More in Innovation?
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Protagonist Therapeutics, Inc.